13F Holdings
中文EN

IRON Disc Medicine, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1816736 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-34.2%
TTM EPS YoY-18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.3%
ROA-36.6%
ROIC (approx.)-40.5%
Asset turnover—

Leverage & solvency

Liabilities / assets13.6%
Debt / equity0.10x
Current ratio20.30x
Interest coverage-61.10x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$170.64M$96.67M$69.26M$33.44M$25.17M
SG&A expense$65.38M$33.05M$21.86M$14.04M$5.76M
Operating income-$236.02M-$129.72M-$91.12M-$47.48M-$30.93M
Interest expense$3.61M$572,000$0—$2.16M
Pretax income-$211.82M-$109.00M-$76.33M-$46.83M—
Income tax$361,000$355,000$99,000$0—
Net income-$212.18M-$109.36M-$76.43M-$46.83M-$35.97M
EBITDA-$235.74M-$129.56M-$91.03M-$47.39M-$30.90M
EPS (basic)-6.01-3.96-3.42-45.05-40.95
EPS (diluted)-6.01-3.96-3.42-45.05-40.95
Weighted avg. shares (diluted)35.30M27.61M22.32M1.04M878,407
Balance sheet
Cash & equivalents$91.14M$192.67M$360.62M$194.79M$88.21M
Short-term investments$700.01M$297.45M$0——
Current assets$803.90M$493.62M$365.66M$198.49M$90.48M
PP&E, net$1.16M$751,000$170,000$168,000$106,000
Total assets$806.88M$496.77M$368.00M$200.21M$92.41M
Current liabilities$36.64M$23.32M$21.44M$22.58M$13.42M
Long-term debt$29.16M$28.32M$0——
Total debt$29.16M$28.32M$0——
Total liabilities$67.05M$53.19M$22.88M$23.61M$14.76M
Shareholders' equity$739.83M$443.59M$345.12M$176.60M-$64.20M
Net debt-$61.99M-$164.35M-$360.62M——
Shares outstanding37.89M29.87M24.36M17.40M909,418
Cash flow statement
Operating cash flow-$180.39M-$93.93M-$73.46M-$42.25M-$27.53M
Capital expenditure$933,000$505,000$89,000$151,000$68,000
Free cash flow-$181.33M-$94.43M-$73.55M-$42.40M-$27.60M
Investing cash flow-$394.30M-$292.33M-$89,000-$151,000-$68,000
Financing cash flow$473.41M$218.31M$239.38M$148.98M$89.93M
Depreciation & amortization$281,000$156,000$100,000$89,000$32,000
Stock-based compensation$34.34M$16.82M$5.53M$2.09M$507,000

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.